Treatment for Myopia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Key-Whitman Eye Center, Dallas, TX
Myopia+2 More
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

The objective of this study is to assess the rate of early intraocular pressure (IOP) increases following implantation of EVO/EVO+ Implantable Collamer Lens (ICL).

Eligible Conditions

  • Myopia
  • Myopic Astigmatism

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 1-6 hours postoperatively

1-6 hours postoperatively
Elevated Intraocular Pressure (IOP) in Fellow Eyes
Elevated Intraocular Pressure (IOP) in Primary Eyes

Trial Safety

Trial Design

0 Treatment Group

200 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1-6 hours postoperatively
Closest Location: Key-Whitman Eye Center · Dallas, TX
Photo of Dallas  1Photo of Dallas  2Photo of Dallas  3
2016First Recorded Clinical Trial
2 TrialsResearching Myopia
10 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able to read, understand and provide written informed consent on the Institutional Review Board (IRB) approved informed consent form (ICF) and provide authorization as appropriate for local privacy regulations.
You have moderate to high myopia.
You have moderate to high myopia with astigmatism.
You are able and willing to return for scheduled follow-up examinations after surgery.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.